Mechanisms of Hepatitis C Virus Escape from Vaccine-Relevant Neutralizing Antibodies
Authors:
- Rodrigo Velázquez-MoctezumaRVRodrigo Velázquez-Moctezuma
- Elias H. AugestadEAElias H. Augestad
- Matteo CastelliMCMatteo Castelli
- Christina Holmboe OlesenCOChristina Holmboe Olesen
- Nicola ClementiNicola Clementi
- Massimo ClementiMCMassimo Clementi
- Nicasio ManciniNMNicasio Mancini
- Jannick PrentoeJPJannick Prentoe
Open Access
Abstract
Hepatitis C virus (HCV) is a major causative agent of acute and chronic hepatitis. It is estimated that 400,000 people die every year from chronic HCV infection, mostly from severe liver-related diseases such as cirrhosis and liver cancer. Although HCV was discovered more than 30 years ago, an efficient prophylactic vaccine is still missing. The HCV glycoprotein complex, E1/E2, is the principal target of neutralizing antibodies (NAbs) and, thus, is an attractive antigen for B-cell vaccine design. However, the high genetic variability of the virus necessitates the identification of conserved epitopes. Moreover, the high intrinsic mutational capacity of HCV allows the virus to continually escape broadly NAbs (bNAbs), which is likely to cause issues with vaccine-resistant variants. Several studies have assessed the barrier-to-resistance of vaccine-relevant bNAbs in vivo and in vitro. Interestingly, recent studies have suggested that escape substitutions can confer antibody resistance not only by direct modification of the epitope but indirectly through allosteric effects, which can be grouped based on the breadth of these effects on antibody susceptibility. In this review, we summarize the current understanding of HCV-specific NAbs, with a special focus on vaccine-relevant bNAbs and their targets. We highlight antibody escape studies pointing out the different methodologies and the escape mutations identified thus far. Finally, we analyze the antibody escape mechanisms of envelope protein escape substitutions and polymorphisms according to the most recent evidence in the HCV field. The accumulated knowledge in identifying bNAb epitopes as well as assessing barriers to resistance and elucidating relevant escape mechanisms may prove critical in the successful development of an HCV B-cell vaccine.Keywords
This publication has 128 references indexed in Scilit:
- Hepatitis C virus epitope exposure and neutralization by antibodies is affected by time and temperatureVirology, 2012
- In Vivo Evaluation of the Cross-Genotype Neutralizing Activity of Polyclonal Antibodies Against Hepatitis C Virus ΔσHepatology, 2011
- Spontaneous Control of Primary Hepatitis C Virus Infection and Immunity Against Persistent ReinfectionGastroenterology, 2010
- Trends in Waiting List Registration for Liver Transplantation for Viral Hepatitis in the United StatesGastroenterology, 2009
- Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activityProceedings of the National Academy of Sciences, 2009
- In vitro selection of a neutralization-resistant hepatitis C virus escape mutantProceedings of the National Academy of Sciences, 2008
- Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virusProceedings of the National Academy of Sciences, 2007
- Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasmaProceedings of the National Academy of Sciences, 2007
- Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis CProceedings of the National Academy of Sciences, 2007
- Production of infectious hepatitis C virus in tissue culture from a cloned viral genomeNature Medicine, 2005